Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Charité - Universitätsmedizin Berlin · Sarah Cannon · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,050
total citations
- FWCI
- 57.49
- Percentile
- 100%
- References
- 24
Citations per year
Authors
13Topics & keywords
Topics
Keywords
- Everolimus
- Medicine
- Octreotide
- Placebo
- Neuroendocrine tumors
- Internal medicine
- Clinical endpoint
- Adverse effect
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.